RESEARCH

Open Access

Risk factors for infection at the saphenous vein harvest site after coronary artery bypass grafting surgery: a retrospective cohort study



Hanna Unosson^{1,2,4*}, Maria Hälleberg Nyman³, Karin Falk Brynhildsen² and Örjan Friberg¹

Abstract

Introduction Surgical site infection after saphenous vein harvest is common, with reported leg wound infection rates ranging from 2 to 24%. There have been few investigations into sex-related differences in complication rates. Moreover, varied effects of smoking have been reported. The aim of this study was to investigate risk factors such as gender and smoking, associated with surgical site infection after vein graft harvesting in coronary artery bypass grafting surgery.

Methods We included 2,188 consecutive patients who underwent coronary artery bypass grafting surgery with at least one vein graft at our centre from 2009 to 2018. All patients were followed up postoperatively. Risk factors for leg wound infection requiring antibiotic treatment and surgical revision were analysed using logistic regression analysis.

Results In total, 374 patients (17.1%) received antibiotic treatment and 154 (7.0%) underwent surgical revision for leg wound infection at the harvest site. Female sex, high body mass index, diabetes mellitus, longer operation time, peripheral vascular disease and direct oral anticoagulants were independently associated with any leg wound infection at the harvest site. Among surgically revised patients, female sex and insulin or oral treatment for diabetes mellitus as well as longer operation time were independent risk factors. Smoking was not associated with leg wound infection.

Conclusion Female sex is associated with increased risk of leg wound infection. The underlying mechanism is unknown. In the current population, previous or current smoking was not associated with an increased risk of leg wound infection.

Keywords Female sex, Leg wound infection, Smoking

*Correspondence:

hanna.unosson@regionorebrolan.se

and Health, Örebro University, Örebro, Sweden

University, Örebro, Sweden

³Faculty of Medicine and Health, University Health Care Research Centre,

Hospital, Örebro, Sweden



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Hanna Unosson

¹Department of Cardiothoracic and Vascular Surgery, Faculty of Medicine

²Faculty of Medicine and Health, School of Health Sciences, Örebro

Örebro University, Örebro, Sweden

⁴Department of Cardiothoracic and Vascular Surgery, Örebro University

Background

In coronary artery bypass grafting (CABG) surgery the saphenous vein is the most common conduit for coronary revascularization, being used in 80% of cases [1]. Surgical site infection (SSI) at the saphenous vein harvest site is more common than sternal wound infections, with reported leg wound infection (LWI) rates ranging from 2 to 24% [2–5]. Leg wound infections have a negative effect on patients' morbidity, quality of life and wellbeing [6]; they prolong hospitalization, may require extensive debridement and surgical procedures and are an economic burden to the health care system [6, 7]. To reduce the risk of LWI, measures such as antibiotic prophylaxis, proper skin disinfection and maintaining an aseptic environment are applied [7-9]. Risk factors associated with LWI include external factors such as the vein harvesting technique [10-12], duration of surgery [13], number of vein grafts [14] and choice of sutures [15-17]. Patientdependent risk factors for LWI include diabetes mellitus (DM), obesity, peripheral vascular disease, impaired renal function and low left ventricular ejection fraction (LVEF) [13, 14, 18].

In different surgical procedures, men are often more affected by SSI than women [19]. Studies regarding sex as a risk factor for sternal wound infection after cardiac surgery show divergent results [4, 5, 20]. However, it has been reported that leg wound complications are actually more common in female patients [14, 18, 21], although further studies are warranted to confirm this.

Smoking is a modifiable risk factor (that is, a behavioral risk factor) that has been associated with wound complications after different types of surgery [22, 23]. Studies investigating LWI after CABG surgery are sparse and no association between smoking and LWI has yet been shown [3, 14].

In conclusion, ambiguity persists regarding the understanding of some potential risk factors for LWI. This study aimed to investigate risk factors for LWI after vein graft harvesting in CABG, with focus on female sex and smoking.

Materials and methods

Study design

This was a retrospective cohort study based on prospectively collected data from a local quality register at a single cardiothoracic centre in Sweden.

Data sources

The Carath Registry is a quality register including pre-, intra- and postoperative patient data. Our study included the following variables: sex, age, body mass index (BMI), glomerular filtration rate (GFR), preoperative haemoglobin (HB), smoking status, DM, vein harvesting technique (conventional or "no-touch" technique, where the vein is harvested along with the perivascular adipose tissue) [24], number of distal anastomoses, LVEF, peripheral vascular disease, degree of urgency (elective or acute), preoperative anticoagulant treatment, type of surgery (CABG or CABG+valve) and operation time. These 15 variables, identified from the Carath Registry, were evaluated regarding their association with LWI. They were selected based on previous research and the authors' own clinical experience, and to ensure inclusion of some less investigated factors.

Patients and perioperative routines

Follow-up data were obtained regarding consecutive patients undergoing CABG alone or CABG in combination with other cardiac surgical procedures, with at least one vein graft, between 1 January 2009 and 31 December 2018 at the Department of Vascular and Cardiothoracic Surgery, Örebro University Hospital, Örebro, Sweden [25].

Preoperatively all elective and acute patients showered with chlorhexidine gluconate (4%). Hair cutting was performed with a hair clipper at the department ward the day before surgery or directly before the operation. Vein harvesting was performed using an open surgical technique. The wound was closed with two or three layers of subcutaneous and intracutaneous monofilament sutures. Between 2009 and 2013, Biosyn 3-0° (Covidien, Minneapolis, MN, USA) was used; from 2014, triclosan-coated Monocryl 3–0° monofilament sutures (Ethicon; Johnson & Johnson, Cincinnati, OH, USA) were used. All patients were treated with perioperative intravenous antibiotic prophylaxis. During 2009-2014, patients received cloxacillin 2 g, starting 25 min before the sternal skin incision. Two hours after the initial dose, another dose of 2 g was administered. For lengthy operations, the dose was repeated every 6 h. Before sternal closure, a final intraoperative dose was given if the previous dose had been administered ≥ 2 h previously. Postoperatively, 2 g of cloxacillin was administered every 8 h for a total duration of at least 24 h. From 2015 onward, a 3 g single dose of benzyl penicillin, administered together with the preoperative dose of cloxacillin, was added. Clindamycin 600 mg was given preoperatively to patients allergic to beta-lactam antibiotics and the dose was repeated after 4 h of surgery, with further postoperative doses given every 8 h for a total of 24 h.

Definition and follow-up of surgical site infection

The study's two outcome variables were all LWIs, and surgical revision for LWI. In this study, LWI was defined as any wound complication for which the patient had been prescribed antibiotic treatment, in accordance with the Centers for Disease Control and Prevention (CDC) classification where one single criterion for superficial

 Table 1
 Baseline characteristics of, and operative factors in, coronary artery bypass grafting (CABG) patients with or without leg wound infection (LWI) at the saphenous vein harvesting site

| | Total No LWI | | Any LWI | Surgical revision | |
|--|--------------|-----------------|---------------|-------------------|--|
| | n=2,188 | n=1,814 (82.9%) | n=374 (17.1%) | n=154 (7.0%) | |
| Patient factors | | | | | |
| Sex, n (%) | | | | | |
| Female | 439 (20) | 335 (18.5) | 104 (27.8) | 48 (31.2) | |
| Male | 1,749 (80) | 1,479 (81.5) | 270 (72.2) | 106 (68.8) | |
| Age, yrs, n (%) | | | | | |
| 0–50 | 65 (3.0) | 52 (2.9) | 13 (3.5) | 4 (2.6) | |
| 51–60 | 305 (13.9) | 256 (14.1) | 49 (13.1) | 16 (10.4) | |
| 61–70 | 821 (37.5) | 693 (38.2) | 128 (34.2) | 67 (43.5) | |
| 71–80 | 843 (38.5) | 685 (37.8) | 158 (42.2) | 56 (36.4) | |
| 81–100 | 154 (7.1) | 128 (7.0) | 26 (7.0) | 11 (7.1) | |
| Body mass index, kg/m ² , n (%) | | | | | |
| <18.5 | 6 (0.3) | 3 (0.1) | 3 (0.8) | 0 (0.0) | |
| 18.5-<25 | 461 (21.1) | 409 (22.6) | 52 (14.0) | 19 (12.3) | |
| 25-<30 | 1,052 (48.1) | 893 (49.3) | 159 (42.5) | 77 (50.0) | |
| ≥30 | 668 (30.5) | 508 (28.0) | 160 (42.7) | 58 (37.7) | |
| Missing | 1 (0.0) | 1 (0.0) | 0 (0.0) | 0 (0.0) | |
| Diabetes mellitus, n (%) | | | | | |
| No | 1,488 (68.0) | 1,281 (70.6) | 207 (55.3) | 72 (46.8) | |
| Insulin-treated | 352 (16.1) | 248 (13.7) | 104 (27.8) | 51 (33.1) | |
| Tablet-treated | 276 (12.6) | 223 (12.3) | 53 (14.2) | 29 (18.8) | |
| Diet-treated | 63 (2.9) | 54 (3.0) | 9 (2.4) | 2 (1.3) | |
| Missing | 9 (0.4) | 8 (0.4) | 1 (0.3) | 0 (0.0) | |
| Haemoglobin, g/L, n (%) | | | | | |
| ≤120 | 278 (12.7) | 217 (12.0) | 61 (16.3) | 31 (20.2) | |
| ≥121 | 1,902 (87.0) | 1,590 (87.6) | 312 (83.4) | 122 (79.2) | |
| Missing | 8 (0.3) | 7 (0.4) | 1 (0.3) | 1 (0.6) | |
| Renal function, (n) % | | | | | |
| Normal function | 929 (42.5) | 776 (42.8) | 153 (41.0) | 60 (38.9) | |
| Mild reduction | 885 (40.5) | 733 (40.4) | 152 (40.6) | 63 (41.0) | |
| Moderate reduction | 337 (15.4) | 272 (15.0) | 65 (17.4) | 28 (18.2) | |
| Severe reduction | 25 (1.1) | 23 (1.3) | 2 (0.5) | 2 (1.3) | |
| Renal failure | 11 (0.5) | 9 (0.5) | 2 (0.5) | 1 (0.6) | |
| Missing | 1 (0.0) | 1 (0.0) | 0 (0.0) | 0 (0.0) | |
| Smoking, n (%) | | | | | |
| Smoker | 232 (10.6) | 184 (10.1) | 48 (12.8) | 25 (16.2) | |
| Ex-smoker ^a | 1.016 (46.4) | 847 (46.7) | 169 (45.2) | 62 (40,3) | |
| Never smoker | 878 (40.1) | 732 (40.4) | 146 (39.0) | 59 (38.3) | |
| Missing | 62 (2.9) | 51 (2.8) | 11 (3.0) | 8 (5.2) | |
| LVEF. n (%) | () | - · () | () | - () | |
| >50% | 1 596 (73 0) | 1 342 (74 0) | 254 (68.0) | 101 (65 6) | |
| 41-50% | 324 (14.8) | 262 (14.4) | 62 (16.6) | 26 (16.9) | |
| 31–40% | 162 (7.4) | 128 (7 1) | 34 (9 1) | 17 (11 0) | |
| <30% | 95 (4.3) | 72 (4.0) | 23 (6.1) | 10 (6.5) | |
| Missing | 11 (0 5) | 10 (0.5) | 1 (0 2) | 0 (0 0) | |
| Anticoagulants, n (%) | | | ···-/ | | |
| Heparin/I MWH | 482 (22 0) | 394 (21 7) | 88 (23 5) | 31 (20 3) | |
| DOAC | 81 (3 7) | 60 (3.3) | 21 (5.6) | 9 (5.8) | |
| No | 1 602 (73 2) | 1 343 (74 0) | 259 (69 3) | 110 (71 4) | |
| Missing | 23 (1 1) | 17 (1 0) | 6 (1 6) | 4 (2 5) | |
| Peripheral vascular disease n (%) | 23 (1.1) | ., (, | 0 (1.0) | . (2.2) | |
| | 149 (6.8) | 113 (63) | 36 (96) | 17 (11 0) | |
| | (0.0) | (0.0) | (>.>) | | |

Table 1 (continued)

| | Total | No LWI | Any LWI | Surgical revision | |
|----------------------------------|--------------|-----------------|---------------|-------------------|--|
| | n=2,188 | n=1,814 (82.9%) | n=374 (17.1%) | n=154 (7.0%) | |
| No | 2,028 (92.7) | 1,693 (93.3) | 335 (89.6) | 137 (89.0) | |
| Missing | 11 (0.5) | 8 (0.4) | 3 (0.8) | 0 (0.0) | |
| Operative factors | | | | | |
| Urgency, n (%) | | | | | |
| Emergency (within 24 h) | 97 (4.4) | 79 (4.4) | 18 (4.8) | 10 (6.5) | |
| Urgent | 779 (35.6) | 638 (35.2) | 141 (37.7) | 57 (37.0) | |
| Elective | 1,292 (59.0) | 1,082 (59.6) | 210 (56.2) | 86 (55.9) | |
| Missing | 20 (1.0) | 15 (0.8) | 5 (1.3) | 1 (0.6) | |
| Type of intervention, | | | | | |
| n (%) | | | | | |
| CABG | 1,724 (78.8) | 1,441 (79.5) | 283 (75.7) | 121 (78.6) | |
| CABG + valve | 408 (18.6) | 331 (18.2) | 77 (20.6) | 26 (16.9) | |
| CABG + other surgery | 56 (2.6) | 42 (2.3) | 14 (3.7) | 7 (4.5) | |
| Vein harvesting technique, n (%) | | | | | |
| No-touch technique | 1,633 (74.6) | 1,345 (74.1) | 288 (77.0) | 119 (77.3) | |
| Conventional technique | 555 (25.4) | 469 (25.9) | 86 (23.0) | 35 (22.7) | |
| Number of graft vessels, n (%) | | | | | |
| 1–2 | 946 (43.2) | 804 (44.3) | 142 (38.0) | 59 (38.3) | |
| 3–4 | 1,167 (53.4) | 956 (52.7) | 211 (56.4) | 82 (53.3) | |
| 5–6 | 75 (3.4) | 54 (3.0) | 21 (5.6) | 13 (8.4) | |
| Operation time, n (%) | | | | | |
| <3 h | 400 (18.3) | 353 (19.5) | 47 (12.6) | 17 (11.0) | |
| 3–5 h | 1,444 (66.0) | 1,200 (66.2) | 244 (65.2) | 92 (59.7) | |
| >5 h | 323 (14.8) | 242 (13.3) | 81 (21.7) | 43 (28.0) | |
| Missing | 21 (0.9) | 19 (1.0) | 2 (0.5) | 2 (1.3) | |

BMI=body mass index; CABG=coronary artery bypass grafting; DOAC=direct oral anticoagulant; LMWH=low-molecular-weight heparin; LVEF=left ventricular ejection fraction

Peripheral vascular disease = one or more of: claudication, carotid occlusion or 50% stenosis, previous or planned intervention on the abdominal aorta, limb arteries or carotids, or amputation for arterial disease

^aEx-smoker>1 month

surgical site infection is "diagnosis of a superficial incisional SSI by a physician or physician designee" [26]. An LWI that had been surgically revised (under local or general anaesthesia) was considered a more severe wound infection; these LWIs were analysed separately. All surgically revised LWIs also required antibiotic treatment.

A registered nurse made a postoperative follow-up call 2 months after the surgery to check for any postoperative infections. A simplified questionnaire based on the validated Additional treatment, Serous discharge, Erythema, Purulent exudate, Separation of deep tissues, Isolation of bacteria, and Stay as inpatient prolonged over 14 days (ASEPSIS) score [27] was used to classify patientreported postoperative symptoms of infection.

Statistical analysis

Categorical variables were expressed as numbers and percentages, and age as median and range. All categorical variables were compared using chi-squared test; for age, Mann-Whitney U test was used. Before the analyses, all ratio data were categorized. Age was divided into decades. Univariable and multivariable logistic regression analyses were used to analyse the relationship of the predictor variables with the outcome. Predictors with p-values ≤ 0.2 in the univariable analysis were added to the multivariable model. The results from the multivariable analysis were reported as adjusted odds ratios (ORs) with 95% confidence intervals (CIs). A p-value of < 0.05 was considered statistically significant.

The statistical analyses were performed using IBM[®] SPSS[®] Statistics version 27 (IBM Corp., Armonk, NY, USA).

Ethics

The study was approved by the Swedish Ethical Review Authority (ID 2020–03103). Because of the retrospective nature of the study no informed consent was obtained.

Results

In total, 2,628 patients underwent CABG surgery during the study period. Of these, 2,188 patients with at least one vein graft were followed up. The study population

Table 2 Baseline characteristics of and operative factors in the included women and men

| Patient factorsUU (J / 199)UU (J / 199 | | Women, <i>n</i> = 439 | Men, <i>n</i> = 1,749 | P-value |
|---|--|-----------------------|-----------------------|---------|
| Age, yra, ediah (min-ma)003:99)003:99003:99SH, kyan', ne(a)'20.50.300.3021.85-0.500.60.04.113.50.03.10.50.9123.00.63.03.100.50.29.10.0023.00.27 (2.52.002.50.03.20.00Sabeta mellitos, ne(b) ^{1,1} 7.27 (2.50.011.216 (0.90.01)0.00Tablets1.27 (2.52.011.216 (0.90.01)1.0012.00.27 (2.52.011.216 (0.90.01)1.0012.00.27 (2.52.011.216 (0.90.01)1.0012.00.97 (3.60.01)1.216 (0.90.01)1.0012.00.97 (3.60.01)1.00 (3.00.01)1.0012.00.97 (3.60.01)1.00 (3.00.01)1.0012.00.02 (3.01.01)0.03 (3.00.01)1.0012.00.02 (3.01.01)0.03 (3.00.01)1.0013.00.02 (3.01.01)0.03 (3.00.01)1.0014.00.02 (3.01.01)0.03 (3.00.01)1.0014.00.02 (3.01.01)0.02 (3.01.01)1.0014.00.02 (3.01.01)0.02 (3.01.01)1.0014.00.02 (3.01.01)0.02 (3.01.01)1.0015.00.02 (3.01.01)0.02 (3.01.01)1.0015.00.02 (3.01.01)0.02 (3.01.01)1.0015.00.02 (3.01.01)0.02 (3.01.01)1.0015.00.02 (3.01.01)0.02 (3.01.01)1.0015.00.02 (3.01.01)0.02 (3.01.01)1.0015.00.02 (3.01.01)0.02 (3.01.01)1.00< | Patient factors | | | |
| BML gong n(%)"UUU< | Age, yrs, median (min–max) | 70.0 (37–89) | 69.0 (30–87) | 0.078 |
| <185<100<10218516338538125-430163381385230163385381230163385385230120120120No272627120120121290160160160212290160160160212120160160160160121120100160160160121120100160160160121120100100100160121120100100100160121120100100100100121100100200100100121100100200100100121100100200100100121100100200100100121100100100100100121100100100100100121100100100100100121100100100100100121100100100100100121100100100100100121100100100100100121100100100100100123100100 <td>BMI, kg/m², n (%)^a</td> <td></td> <td></td> <td>0.305</td> | BMI, kg/m ² , n (%) ^a | | | 0.305 |
| 18.5-25106 (42)352 (20.3)25 -30161 (33.7)552 (20.3)23.0163 (37.1)552 (20.3)21.0165 (37.2)17.16 (9.8)Non125 (27.2)17.16 (9.8)Non137 (31.4)141 (8.0)21.00137 (31.4)141 (8.0)21.0110.20 (9.2)10.20 (9.2)Nonal Inction (9.6)*137 (31.4)141 (8.0)Ranif Jucticon (9.6)*137 (31.4)10.20 (9.2)Nonal Inction (9.6)*137 (31.4)10.20 (9.2)Nonal Inction (9.6)*12.20655 (9.3)Nonal Inction (9.6)*10.02 (9.1)6.05 (9.6)Nonage reduction10.02 (9.1)6.05 (9.6)Nonage reduction10.02 (9.1)6.05 (9.6)Sever reduction10.116.05 (9.6)Sonker6.11 (9.7)6.05 (9.6)Sonker6.01 (9.8)6.05 (9.6)Nonage reduction10.68 (9.6)10.20 (9.6)Sonker10.60 (9.8)6.65 (9.6)Sonker10.60 (9.6)12.02 (9.6)Sonker10.60 (9.6)12.02 (9.6)Sonker10.10 (9.6)12.02 (9.6)Sonker10.10 (9.6)12.02 (9.6)Sonker10.10 (9.6)12.02 (9.6)Sonker10.10 (9.6)10.10 (9.6)Sonker10.10 (9.6)10.10 (9.6)Sonker10.10 (9.6)10.10 (9.6)Sonker10.10 (9.6)10.10 (9.6)Sonker10.10 (9.6)10.10 (9.6)Sonker10.10 (9.6)10.10 (9.6) <td><18.5</td> <td>2 (0.5)</td> <td>4 (0.2)</td> <td></td> | <18.5 | 2 (0.5) | 4 (0.2) | |
| 2n-200108(83)84000)>370163(73)55(28)Notesmellitus, n(%) ^{4,4} 163(73)55(28)National (1993)27(20)12(20)National (1993)27(20)12(20)1210120 (20)120(20)1210127(20)120(20)1210127(20)120(20)Nomal function, n(%) ¹ 123(280)806(461)Nomal function, n(%) ¹ 123(280)806(451)Nomal function102(25)806(451)Nomal function102(25)806(26)Severe neutricon10(25)40.89Severe neutricon10(25)80.60Severe neutricon10(25)80.60Severe neutricon10.12(5)80.60Severe neutricon10.12(5)80.60Severe neutricon10.12(5)80.60Severe neutricon10.12(5)80.60Severe neutricon10.12(5)80.60Severe neutricon10.6080.60Severe neutricon80.6010.00Severe neutricon10.6010.00Severe neutricon10.12(5)10.00Severe neutricon10.12(5)10.00Severe neutricon10.12(5)10.00Severe neutricon10.12(5)10.00Severe neutricon10.12(5)10.00Severe neutricon10.12(5)10.00Severe neutricon10.12(5)10.00Severe neutricon10.0010.00Severe neutricon10.0010.00Se | 18.5-<25 | 106 (24.1) | 355 (20.3) | |
| >a0164/7.1163/7.317.000Dates mellitus, n(%)**56.07.356.07.350.00.7No27.02.2212.16 (0.9.3)12.16 (0.9.3)12.16 (0.9.3)Bemogloin, g/L, n(%)**29.02.014.00.012.10212029.08.016.03.02.012.10Normal Induction19.04.3.086.04.1.110.00.0Mid reduction19.04.3.086.04.0.110.00.0Mid reduction19.04.3.060.30.010.00.0Severe reduction10.05.1.160.30.010.00.0Severe reduction11.05.1.160.30.010.00.0Severe reduction10.05.1.160.03.010.00.0Severe reduction10.05.1.160.03.010.00.0Severe reduction10.05.1.160.03.010.00.0Severe reduction10.05.1.160.03.010.00.0Severe reduction10.05.1.160.03.010.00.0Severe reduction10.05.1.160.03.010.00.0Severe reduction10.00.010.00.010.00.0Severe reduction10.00.010.00.010.00.0Severe reduction10.00.010.00.010.00.0Severe reduction10.00.010.00.010.00.0Severe reduction10.00.010.00.010.00.0Severe reduction10.00.010.00.010.00.0Severe reduction10.00.010.00.010.00.0Severe reduction10.00.010.00.010.00.0Severe reduction10.00.0 <td>25-<30</td> <td>168 (38.3)</td> <td>884 (50.6)</td> <td></td> | 25-<30 | 168 (38.3) | 884 (50.6) | |
| <table-container>Dates mellita, n (%)**0000Yes16000, 1216 (098)No272 (024)1216 (098)Haenogtoin, g/L, n (%)*299 (86)1603 (920)212299 (86)1603 (920)Start function, n (%)*299 (86)1603 (920)Normal function, (%)*290 (86)895 (938)Normal function, (%)*800 (80,1)100Normal function, (%)*112 (25,1)800 (80,1)Start function, (%)*112 (25,1)40.03Start function, (%)*112 (25,1)40.03Start function, (%)*100 (80,1)100 (80,1)Start f</table-container> | ≥30 | 163 (37.1) | 505 (28.9) | |
| YesSole (32, 32, 62, 32)Sole (32, 32, 62, 32)No22, 62, 23, 24, 24, 34, 34, 34, 34, 34, 34, 34, 34, 34, 3 | Diabetes mellitus, n (%) ^{a, f} | | | 0.002 |
| No22 (82)1,21 (60.8)Haenoglobin, gl.n (60.8)20 (80.1)141 (80.1)312030 (31.4)141 (80.1)212120 (80.1)10.60 (32.0)Sanal function, n (80"130 (80.0)806 (46.1)Constant function10 (80.1)20 (10.0)Mild reduction10 (80.1)20 (10.0)Mild reduction10 (25.1)20 (80.1)Severe reduction10 (25.1)40.80Severe reduction10 (26.1)168 (98.1)Severe reduction10 (80.1)60.3)20 (10.1)Severe reduction10 (80.1)168 (98.1)20 (10.1)Severe reduction10 (80.1)168 (98.1)20 (10.1)Severe reduction10 (80.1)168 (98.1)20 (10.1)Severe reduction10 (80.1)12 (10.1)20 (10.1)Severe reduction10 (80.1)12 (10.1)20 (10.1)Severe reduction10 (80.1)12 (10.1)20 (10.1)20 (10.1)Severe reduction10 (80.1)12 (10.1)20 (10.1)20 (10.1)Severe reduction10 (80.1)12 (10.1)12 (10.1)20 (10.1)Severe reduction10 (10.1)12 (10.1)20 (10.1)20 (10.1)Severe reduction12 (28.1)12 (10.1)12 (10.1)20 (10.1)Severe reduction13 (10.1)13 (10.1)13 (10.1)13 (10.1)Severe reduction13 (10.1)13 (10.1)13 (10.1)13 (10.1)Severe reduction13 (10.1)13 (10.1)13 (10.1)13 (1 | Yes | 165 (37.8) | 526 (30.2) | |
| Haenoglobin g/L n (%)b ^{16.0} | No | 272 (62.2) | 1,216 (69.8) | |
| s120137 (14)14 (160)s121137 (14)1630 (92.0)s1211630 (92.0)1630 (92.0)Renal function, n (%) ⁴ 122 (80)695 (98.9)Mild reduction101 (25.1)227 (13.0)Sever reduction110 (25.1)227 (13.0)Sever reduction110 (25.1)60.3Sever reduction110 (25.1)60.3Sever reduction110 (25.1)60.3Sever reduction100 (81.1)68 (98.0)Sever reduction100 (81.1)68 (60.2)Sever reduction106 (81.1)68 (60.2)Never smaker106 (81.1)68 (60.2)Sever reduction136 (70.0)134 (73.7)Sever reduction136 (70.0)132 (7.6)Sever reduction136 (80.0)132 (7.6)Sever reduction130 (63.0)132 (7.6)Sever reduction130 (73.0)132 (7.6)Sever reduction132 (7.6)132 (7.6)< | Haemoglobin, g/L, n (%) ^{b, g} | | | <0.001 |
| 121299 (86)1603 (92.0)Renaf function, (%)a ⁴ 23 (28.0)806 (64.1)Mild reduction190 (43.3)655 (73.8)Mid reduction110 (25.1)24 (0.8)Sever reduction11 (2.5)14 (0.8)Benaf failure11 (2.5)14 (0.8)Sonking, (%) ^{6,1} 562 (40.0)Exemsder ¹ 100 (38.1)62 (40.0)Newer smoker106 (38.1)62 (40.0)Veer smoker ¹ 04 (45.7)128 (73.7)15 (74.0)74 (16.3)250 (14.4)31-40%30 (6.8)32 (7.6)31-40%30 (6.8)32 (7.6)31-40%13 (2.5)64 (3.0)31-40%13 (2.5)64 (3.0)31-40%13 (2.5)64 (3.0)31-40%13 (2.5)64 (3.0)31-40%13 (2.5)64 (3.0)31-40%13 (2.5)64 (3.0)30AC13 (2.5)16 (8.9)30AC14 (3.2)10 (3.1)30AC14 (3.1)14 (3.0)30AC14 (3.2)10 (3.1)30AC14 (3.2)10 (3.1)30AC14 (3.2)10 (3.1)31-40%14 (3.2)10 (3.1)31-40%14 (3.2)10 (3.1)31-40%14 (3.2)10 (3.1)31-40%14 (3.2)14 (3.2)10 (3.1) <tr< td=""><td>≤120</td><td>137 (31.4)</td><td>141 (8.0)</td><td></td></tr<> | ≤120 | 137 (31.4) | 141 (8.0) | |
| Renal function (n 96) ^d | ≥121 | 299 (68.6) | 1,603 (92.0) | |
| Normalfunction122 (28.0)806 (46.1)906 (43.1)806 (46.1)906 (40.1) </td <td>Renal function, n (%)^d</td> <td></td> <td></td> <td>< 0.001</td> | Renal function, n (%) ^d | | | < 0.001 |
| Mid reduction190 (43.)695 (98)1Moderate reduction110 (25.)27 (130.)1Renal faiture10 (25.)40.08)1Sonker61.0160.30.1Sonker60 (30.)86 (50.2)1Ex-snoker1160 (30.1)86 (50.2)1Never smoker1160 (30.1)85 (50.2)1Never smoker1160 (30.1)85 (50.2)1Never smoker160 (30.1)85 (50.2)1Never smoker160 (30.1)120.0)1145.0%15 (70.0)120.0)1145.0%15 (70.0)120.0)1140%115 (20.0)120.0)1140%010 (30.0)120.0)1140%010 (30.0)120.0)1140%113 (20.0)120.0)1140%113 (20.0)120.0)1140%113 (20.0)120.0)1150%110 (30.0)120.0)1150%110 (30.0)120.0)1150%110 (20.0)120.0)1150%110 (20.0)100.0)1150%110 (20.0)100.0)1150%110 (20.0)100.0)1150%110 (20.0)100.0)1150%110 (20.0)100.0)1150%110 (20.0)100.0)1150%110 (20.0)100.0)1150%110 (20.0)100.0)116010 (20 | Normal function | 123 (28.0) | 806 (46.1) | |
| Moderate reduction110 (25.1)227 (13.0)Severe reduction11 (2.5)10.03Severe reduction11 (2.5)6.0.3)Sender failure6.0.106.0.3)Smoker, P(%) ^{6, n} 6.0.1086.5 (50.2)Severe smoker6.0.0.3186.5 (50.2)Never smoker16.0.0.3186.5 (50.2)Never smoker16.0.0.3186.5 (50.2)Never smoker16.0.0.3186.5 (50.2)Never smoker15.0.70.012.81 (73.7)1.50%12.81 (73.7)18.850%31.40.9250 (14.4)41.50%30.6.8)32.0.631.40%104.076.4320%10.41.976.4320%10.42.969.40.120%12.2.869.40.1No11.0.1.912.9.1.9No11.0.1.912.9.1.9No11.0.1.912.9.1.9No10.6.9.112.9.1.9No11.0.1.912.9.1.9No11.0.1.912.9.1.9No11.0.1.912.9.1.9No10.6.9.112.9.1.9No10.6.9.112.9.1.9No10.6.9.110.9.1.9No10.9.1.910.9.1.9No10.9.1.910.9.1.9No10.9.1.910.9.1.9No10.9.1.910.9.1.9No10.9.1.910.9.1.9No10.9.1.910.9.1.9No10.9.1.910.9.1.9No10.9.1.910.9.1.9No< | Mild reduction | 190 (43.3) | 695 (39.8) | |
| Sever enduction11(2.5)14(0.8)Rend failure5(1)6(3.3)Smoking, (%) ^{6,1} 6(3.8) | Moderate reduction | 110 (25.1) | 227 (13.0) | |
| <table-container>Benaffailure5(1)6(0.3)Smoker4(15.2)160.08,0)Smoker6(0.38,1)856.02,0)Exemoker160.08,1)856.02,0)Neversmoker106.08,1)856.02,0)Neversmoker106.08,1)856.02,0)VEFL n(%)^{4,1}157.00128.173,7)14-50%130.10,0)120.10,0)31-40%06.8,0132.0,6)31-40%06.8,0132.0,6)31-40%104.0,0120.6,031-40%140.5,069.0,1031-40%132.0,6)69.0,1031-40%132.0,6)69.0,1031-40%132.0,6)69.0,1031-40%132.0,6)69.0,1031-40%132.0,6)69.0,1031-40%132.0,6)69.0,1031-40%132.0,6)69.0,1031-40%132.0,6)132.0,6031-40%142.0,00132.0,6031-40%141.0,10140.0,0031-40%140.0,00140.0,0031-40%140.0,00140.0,0031-40%140.0,00140.0,0031-40%140.0,00140.0,0031-40%140.0,00140.0,0031-40%140.0,00140.0,0031-40%140.0,00140.0,0031-40%140.0,00140.0,0031-40%140.0,00140.0,0031-40%140.0,00140.0,0031-40%140.0,00140.0,0031-40%140.0,00140.0,0031-40%140.0,00140.0,00<</table-container> | Severe reduction | 11 (2.5) | 14 (0.8) | |
| <table-container>Sinoking, n(%)^{c,h}Smoker60 (33.)68 (63.)Kexmoker60 (33.)68 (63.)Never smoker19 (64.7)62 (40.0)VEF, n(%)^{6,1}28 (14.7)14-50%74 (16.9)29 (14.4)31-40%30 (8.8)32 (76.1)31-40%30 (8.8)32 (76.1)31-40%13 (25.9)39 (21.3)Anticagularis, n(%)^{k,j}13 (25.9)39 (21.3)DAC12 (28.0)39 (21.3)DAC13 (25.9)39 (21.3)DAC14 (29.1)129 (17.2)DAC14 (29.1)129 (17.2)No13 (25.9)39 (21.3)DAC40 (29.1)129 (17.2)No14 (17.1)129 (17.2)No10 (17.1)129 (17.2)No10 (29.1)129 (17.2)No10 (29.1)129 (17.2)No10 (29.1)129 (17.2)No10 (29.1)10.3 (17.1)No10 (29.1)10.3 (17.1)No10 (29.1)10.3 (17.1)No10 (29.1)10.3 (17.1)No10 (29.1)10.3 (17.1)No10 (29.1)10.3 (17.1)No10 (29.1)10.3 (17.1)<!--</td--><td>Renal failure</td><td>5 (1.1)</td><td>6 (0.3)</td><td></td></table-container> | Renal failure | 5 (1.1) | 6 (0.3) | |
| Sinoker64(152)189(98)180Ex-moder ¹ 16(31)85(502)Never smoker ¹ 66(30)85(502)Never smoker16(30)85(502)Never smoker15(720)128(73,7)55%30(8)132(73,7)141-50%00.8)132(76)131-40%00.8)132(76)131-40%00.8)132(76)133%01.8)132(52)64(3)30%131(52)69(4)1DOAC12.28)69(4)1DoA117.1318(6)1No117.1318(6)1No162(93,20)162(93,20)1No160(92,9)162(93,20)1No162(93,20)162(93,20)1No162(93,20)162(93,20)1No19(12)162(93,20)1No19(12)00(34,60)1Urgenty19(42,20)00(34,60)1Urgenty19(42,30)03(13,30)1CAG140(78,10)142,70)1CAG140(80,10)11CAG1335(76,31)11CAG1345(74,91)142,70)1CAG144,73144,73)142,70)1CAG144,73143,70)142,70)1CAG144,73143,70)142,70)1CAG144,73143,70)142,70)1CAG144,73143,70)14 | Smoking, n (%) ^{c, h} | | | < 0.001 |
| Examoker1160 (38.1)856 (50.2)Never smoker164 (57.0)62.0 (0.0)Never smoker164 (57.0)12.81 (73.7)>50%74.16.9)250 (14.4)41-50%13.0 (20.0)13.0 (20.0)31-40%10.8.330.6 (20.0)30%10.8.376.43Anticoagulants, n(%) ^{1k,1} 12.2.869.0 (20.0)DOAC12.2.8.069.0 (20.0)DOAC12.2.8.069.0 (20.0)No31.0 (1.3.0)1.90 (20.0)No10.6.9.01.82 (20.0)No06.02.9.01.62 (20.2)Pertive factors10.6.01.62 (20.2)Pertive factors10.001.62 (0.0)Urgent (Within 24.h)20.62.01.60 (20.0)Urgent (Staffer Age)10.61.01.60 (20.0)Urgent (Staffer Age)10.61.01.60 (20.0)Urgent (Staffer Age)10.62.01.60 (20.0)Urgent (Staffer Age)10.62.01.60 (20.0)Urgent (Staffer Age)10.62.01.60 (20.0)Urgent (Staffer Age)10.62.01.60 (20.0)CASG10.62.01.60 (20.0)1.60 (20.0)CASG10.62.01.62.01.60 (20.0)CASG10.62.01.62.01.60 (20.0)CASG10.62.01.62.01.60 (20.0)CASG10.62.01.62.01.60 (20.0)CASG10.62.01.62.01.60 (20.0)CASG10.62.01.62.01.60 (20.0)CASG10.62.01.62.01.60 (20.0) | Smoker | 64 (15.2) | 168 (9.8) | |
| Never smoker196 (46.7)682 (40.0) $UEF, reg)s4,1$ | Ex-smoker ¹ | 160 (38.1) | 856 (50.2) | |
| LVEF, n(%)0.828>50%1,50%1,281 (73,7)>1-50%250 (14,4)>1-40%30 (50,0)250 (14,4)>30%312 (7,5)369 (21,3)Anticogulants, n(%) ^[k] 13 (25,0)369 (21,3)DOAC12 (28,0)64 (40,0)No12 (28,0)120 (74,7)Peripheral vascular disease, n (%) ^[k,k] 1,21 (24,3)Yes31 (71,1)181 (6.8)No140 (20,0)120 (20,2)Operative factors19 (23,0)Urgency, n(%) ^[k] 19 (12,0)Energency (within 24 h)27 (62,0)Urgent19 (23,0)Affed factors19 (23,0)Urgent (within 24 h)29 (25,6)Urgent (Safe factors)100 (36,6)Elective 20 (26,1)1,400 (80,1)CABG other surgery10 (23,0)Affed factors10 (23,0)CABG other surgery10 (23,0)CABG other surgery10 (23,0)Convention factoring (%)1,335 (76,3)Convention factoring (%)1,335 (76,3)Convention factoring (%)1,335 (76,3)Convention factoring (%)1,335 (76,3)Li1,404,301,335 (76,3)Convention factoring (%)1,21 (48,3)Si (24,3)1,355 (76,3)Cali1,21 (48,3)Cali1,21 (48,3)Cali1,21 (48,3)Cali1,21 (48,3)Cali1,21 (48,3)Cali1,21 (48,3)Cali1,21 (48,3)Cali1,21 (48,3) <td>Never smoker</td> <td>196 (46.7)</td> <td>682 (40.0)</td> <td></td> | Never smoker | 196 (46.7) | 682 (40.0) | |
| >50%1,281 (7.3,7)41-50%250 (14.4)31-40%30 (6.8)250 (14.4)31-40%30 (6.8)132 (7.6)30%19 (3.3)7.6 (3.3)Anticoagulants, n(%) ^{5,1} 132 (5.9)69 (21.3)Phatri/LMWH132 (5.9)69 (21.3)DOAC12 (2.8)69 (4.0)No12 (1.3)1.21 (1.4)Perpheral vascular disease, n (%) ^{8,1} 1.21 (1.3)Yes04 (0.9)1.22 (93.2)Yes10 (2.9)1.62 (93.2)No162 (93.2)1.62 (93.2)Solar disease, n (%) ^{8,1} 1.8 (6.8)1.00 (1.6)Yes10 (2.9)1.62 (93.2)Yes10 (2.9)1.62 (93.2)Yes10 (2.9)1.62 (93.2)Solar disease, n (%) ^{8,1} 1.00 (8.1)1.00 (8.1)Yes29 (52.6)1.06 (3.6)Urgent29 (52.6)1.40 (8.01)Urgent fortor1.02 (93.2)1.00 (9.1)CABG + valve1.02 (93.2)1.00 (9.1)CABG + valve1.02 (9.2)1.00 (9.1)CABG + valve1.02 (9.2)1.00 (9.1)CABG + valve1.02 (9.2)1.00 (9.1)Conventional technique en (%)1.33 (7.6)1.00 (9.1)Noto technique en (%)1.33 (7.6)1.00 (9.1)Conventional technique en (%)1.33 (7.6)1.00 (9.1)Conventional technique en (%)1.33 (7.6)1.00 (9.1)Solar distribution en (%)1.33 (7.6)1.00 (9.1)Solar distribution en (%)1.33 (7.6) <t< td=""><td>LVEF, n (%)^{d, i}</td><td></td><td></td><td>0.828</td></t<> | LVEF, n (%) ^{d, i} | | | 0.828 |
| <table-container>41-50%74 (16.9)250 (14.4)31-40%30 (6.8)132 (7.6)<30%</table-container> | >50% | 315 (72.0) | 1,281 (73.7) | |
| <table-container>$31-40\%$$30(68)$$132(76)$$\pm 30\%$$9(43)$$76(43)$$Anticogulants, n(%)^{h,j}$$13(25)$$369(21.3)$$Pepatin/LMWH$$132(59)$$369(21.3)$$DoAC$$12(28)$$69(4.0)$$No$$317(1.3)$$291(74.7)$$Perpheral vascular disease, n(%)^{h,k}$$12(29.2)Yer317(1.3)$$18(6.8)$$No$$40602.9$$1622(93.2)$$Operative factors$$U$$0.020$$Vertar (Mithin 24h)$$29(52.9)$$00(34.6)$<math>Urgent$109(41.2)$$00(34.6)$$Vertar (Mithin 24h)$$29(52.6)$$1.03(61.4)$$Vertar (Mithin 24h)$$29(52.6)$$0.33(17.3)$$CABG$$102(3.9)$$303(17.3)$$CABG$$102(3.9)$$303(17.3)$<math>CABG + other surgery$102(3.9)$$303(17.3)$<math>CABG + other surgery$102(3.9)$$303(17.3)$<math>Convention function$12(2.9)$$303(17.3)$<math>Convention function$12(3.9)$$335(76.3)$<math>Onto the chnique$104(3.7)$$335(76.3)$<math>Onto the chnique$12(48.3)$$35(2.0)$$1-2$$21(48.1)$$35(4.0)$$1-2$$21(48.1)$$35(4.0)$$1-2$$21(48.1)$$35(4.0)$$1-2$$31(4.1)$$35(4.0)$$1-2$$31(4.1)$$35(4.0)$$1-2$$31(4.1)$$35(4.0)$$1-2$$31(4.1)$$35(4.0)$$1-2$$31(4.1)$$35(4.0)$$1-2$$31(4.1)$</math></math></math></math></math></math></math></table-container> | 41–50% | 74 (16.9) | 250 (14.4) | |
| ≤3%9(4.3)76(4.3)Anticoagulants, n(%) ^{h,1} 0.073Heparin/LMWH13 (259)DOAC12 (2.8)OA3117.13Peripheral vascular disease, n(%) ^{h, k} 0.291 (74.7)Peripheral vascular disease, n(%) ^{h, k} 116 (8.8)No317.13No14 (6.8)No406 (9.2)Operative factors0.021Urgenç, n(%) ^{e,1} 10 (3.0)Emergency (within 24 h)27 (6.2)Quergent70 (4.0)Urgençt0.003 (6.4)Elective2020Operative factors0.003Urgençt1.400 (80.1)CABG324 (73.8)Alba S-valve0.303 (17.3)CABG+ valve102.3)CABG+ valve102.3)CABG+ valve102.3)Conventional technique286 (5.9)Conventional technique114 (23.7)1-2214 (84.3)3-4.4214 (84.3)3-4.4214 (84.3)3-4.4214 (84.3)3-4.4214 (84.3)3-4.4214 (84.3)3-4.4214 (84.3)3-4.4214 (84.3)3-4.4214 (84.3)3-4.4214 (84.3)3-4.4214 (84.3)3-4.4214 (84.3)3-4.4214 (84.3)3-4.4214 (84.3)3-4.4214 (84.3)3-4.4214 (84.3)3-4.4214 (84.3)3-5.4214 (84.3)3-6.4214 (84.3)3-6.421 | 31–40% | 30 (6.8) | 132 (7.6) | |
| Anticoagulants, n (%)s ^{1,1} 0.073Heparin/LMWH13 (259)369 (21.3)DOAC12 (28)69 (40.9)No12 (28)129 (74.7)Rentpheral vascular disease, n (%)s ^{1,k} 117 (13.0)129 (74.7)Yes31 (7.1)118 (6.8)1No406 (92.9)162 (93.2)1Operative factors12 (26.2)1.62 (93.2)Urgenty, n (%)s ^{1,k} 7 (62.2)70 (4.0)10.02Energency (within 24 th)27 (62.2)1.06 (14.9)1Urgent20 (25.6)1.06 (14.9)1CABG22 (92.6)1.06 (14.9)1CABG162 (39.1)303 (17.3)1CABG102 (39.1)303 (17.3)1CABG105 (23.9)303 (17.3)1CABG102 (14.9)135 (76.3)1CABG102 (14.9)135 (76.3)1CABG+valve102 (14.9)141 (23.7)1CABG+valve140 (23.7)11CABG+valve128 (63.9)1.35 (76.3)1Conventional technique141 (23.1)141 (23.7)1Chater technique128 (14.9)152 (14.9)11-2114 (14.9)155 (24.6)11-2124 (14.9)152 (14.9)12-4124 (14.9)155 (24.6)11-2124 (14.9)152 (14.9)12-4124 (14.9)155 (24.6)11-2124 (14.9)152 (14.9)12-4124 (14 | ≤30% | 19 (4.3) | 76 (4.3) | |
| Heparin/LMWH113 (25.9)369 (21.3)DOAC12 (2.8)69 (4.0)No311 (1.3)1.29 (74.7)Paripheral vascular disease, n (%) ^{a, k} 1.29 (74.7)0.17Yes31 (7.1)1.8 (6.8)0.17No06 (92.9)1.622 (93.2)0.17Operative factors1.62 (93.2)1.62 (93.2)Urgency, n (%) ^{6, l} 27 (6.2)0.00 (3.4)Urgency (within 24 h)27 (6.2)0.00 (3.4)Urgent1.99 (25.2)1.063 (6.1)Elective2.99 (25.2)1.063 (1.3)CABG3.24 (73.8)1.400 (80.1)CABG3.24 (73.8)1.400 (80.1)CABG1.02 (3.2)0.33 (17.3)CABG1.02 (3.2)0.33 (17.3)CABG1.02 (3.2)0.33 (17.3)CABG1.400 (80.1)1.400 (80.1)CABG1.400 (80.1)1.400 (80.1)CABG1.62 (3.9)0.33 (17.3)CABG1.62 (3.9)0.33 (17.3)CABG1.400 (80.1)1.400 (80.1)CABG1.400 (80.1)1.400 (80.1)CABG1.4100 (80.1)1.400 (80.1) <t< td=""><td>Anticoagulants, n (%)^{b, j}</td><td></td><td></td><td>0.073</td></t<> | Anticoagulants, n (%) ^{b, j} | | | 0.073 |
| DOAC12 (2.8)69 (4.0)No311 (71.3)1.291 (74.7)Peripheral vascular disease, n (%) ^{1,1} 31 (7.1)18 (6.8)No31 (7.1)118 (6.8)No0.60 (9.9)1.622 (93.2)Operative factors | Heparin/LMWH | 113 (25.9) | 369 (21.3) | |
| No311 (71.3)1,291 (74.7)Peripheral vascular disease, m(%) ^{a,k} 0.817Yes31 (7.1)118 (6.8)No406 (92.9)1,622 (93.2)Cperative factors | DOAC | 12 (2.8) | 69 (4.0) | |
| Peripheral vascular disease, n (%) ^{8, k} 0.817Yes31 (7.1)118 (6.8)No466 (9.2)1,622 (9.3.2)Operative factors | No | 311 (71.3) | 1,291 (74.7) | |
| Yes31 (7.1)118 (6.8)No406 (9.9)1,62 (9.3.2)Operative factorsUrgency. (%) ^{6,1} Urgency. (%) ^{6,1} 27 (6.2)Emergency (within 24 h)27 (6.2)Urgent70 (4.0)Urgent29 (5.2)Elective209 (5.2)Elective209 (5.2)Type of intervention, n (%)324 (73.8)CABG1,400 (80.1)CABG valve105 (23.9)CABG valve103 (37.3)CABG valve103 (30.1)Conventional technique, n(%)28 (67.9)No-touch technique14 (32.1)Valmare of graft vessels, n (%)1148.1)1-211 (48.1)1-335 (54.6)1-412 (24.83)5-616 (3.6)5-616 (3.6)Coperation time, n(%) ^{b, m} 0.28663 h78 (7.9)21 Ab78 (7.9)22 (85.9)32 (18.6) | Peripheral vascular disease, n (%) ^{a, k} | | | 0.817 |
| No 460 (92.9) 1,622 (93.2) Operative factors | Yes | 31 (7.1) | 118 (6.8) | |
| Operative factors 0.002 Urgency, (%) ^{6,1} 70 (4.0) Emergency (within 24 h) 70 (4.2) Urgent 70 (4.0) Elective 20 (52.6) Elective 20 (52.6) Type of intervention, n (%) 1,400 (80.1) CABG 324 (73.8) 1,400 (80.1) CABG + valve 105 (23.9) 303 (17.3) CABG + valve 105 (23.9) 303 (17.3) CABG + other surgery 102.3) 46 (26.0) No-touch technique, n(%) 141 (32.1) 41 (32.7) No-touch technique 298 (67.9) 1,335 (76.3) Canventional technique 298 (67.9) 1,335 (76.3) No-touch technique 298 (67.9) 1,335 (76.3) Canventional technique 298 (67.9) 1,335 (76.3) Canventional technique 298 (67.9) 1,335 (76.3) 1-2 11 (48.1) 75 (42.0) 1 1-2 21 (48.3) 59 (34.0) 1 2-4 12 (48.3) 59 (34.0) 1 2-4 12 (48.3) 59 (34.0) 1 2-6 16 (| No | 406 (92.9) | 1,622 (93.2) | |
| Urgency, n(%) ^{e,1} 0.002Emergency (within 24 h)27 (6.2)70 (4.0)Urgent179 (4.1.2)600 (34.6)Elective29 (52.6)1,63 (61.4)Elective324 (73.8)1,400 (80.1)CABG324 (73.8)303 (17.3)CABG + valve105 (23.9)303 (17.3)CABG + other surgery10 (2.3)46 (2.6)Vert harvesting technique, n(%)1,335 (76.3)0.001No-touch technique298 (67.9)1,335 (76.3)Conventional technique141 (32.1)414 (23.7)I-2211 (48.1)735 (42.0)1-2212 (48.3)955 (54.6)5-616 (3.6)55 (34.6)5-616 (3.6)50 (3.6)Coperation time, n(%) ^{b,m} 78 (7.9)322 (18.6) | Operative factors | | | |
| Emergency (within 24 h) 27 (6.2) 70 (4.0) Urgent 179 (41.2) 600 (34.6) Elective 229 (52.6) 1,063 (61.4) Type of intervention, n (%) 1,400 (80.1) 0.006 CABG 324 (73.8) 1,400 (80.1) 0.001 CABG 105 (23.9) 303 (17.3) 0.001 CABG+ valve 102 (3) 303 (17.3) 0.001 CABG+ other surgery 102 (3) 46 (2.6) 0.001 Vein harvesting technique, n (%) 298 (67.9) 1,335 (76.3) 0.001 No-touch technique 298 (67.9) 1,335 (76.3) 0.002 Conventional technique 141 (32.1) 41 (32.7) 0.0052 Number of graft vessels, n (%) 11 (48.1) 735 (42.0) 0.052 1-2 211 (48.3) 95 (54.6) 0.052 1-2 12 (48.3) 95 (54.6) 1 3-4 12 (48.3) 95 (54.6) 0.0286 5-6 16 (36.0) 10.286 0.286 Operation time, n (%) ^{b,m} 22 (18.6) 0.286 | Urgency, n (%) ^{e, l} | | | 0.002 |
| Urgent 179 (41.2) 600 (34.6) Elective 229 (52.6) 1,063 (61.4) Type of intervention, n (%) | Emergency (within 24 h) | 27 (6.2) | 70 (4.0) | |
| Elective 29 (52.6) 1,063 (61.4) Type of intervention, n (%) 0.006 CABG 324 (73.8) 1,400 (80.1) CABG+valve 105 (23.9) 303 (17.3) CABG+other surgery 10 (2.3) 46 (2.6) Verin harvesting technique, n (%) <0.001 | Urgent | 179 (41.2) | 600 (34.6) | |
| Type of intervention, n (%) 0.006 CABG 324 (73.8) 1,400 (80.1) CABG+valve 105 (23.9) 303 (17.3) CABG+other surgery 10 (2.3) 46 (2.6) Vein harvesting technique, n (%) 1,335 (76.3) -0.001 No-touch technique 298 (67.9) 1,335 (76.3) -0.001 Conventional technique 141 (32.1) 414 (23.7) -0.052 1-2 114 (83.1) 735 (42.0) -0.052 1-2 211 (48.1) 735 (42.0) -0.052 5-6 16 (3.6) 59 (3.4) -0.286 Operation time, n (%) ^{b, m} | Elective | 229 (52.6) | 1,063 (61.4) | |
| CABG 324 (73.8) 1,400 (80.1) CABG + valve 105 (23.9) 303 (17.3) CABG + other surgery 10 (2.3) 46 (2.6) Vein harvesting technique, n (%) 298 (67.9) 1,335 (76.3) No- touch technique 298 (67.9) 1,335 (76.3) Conventional technique 141 (32.1) 414 (23.7) Number of graft vessels, n (%) 0.052 1-2 211 (48.1) 735 (42.0) 3-4 212 (48.3) 955 (54.6) 5-6 16 (3.6) 59 (3.4) Operation time, n (%) ^{b, m} 0.286 <3 h | Type of intervention, n (%) | | | 0.006 |
| CABG+valve 105 (23.9) 303 (17.3) CABG+other surgery 10 (2.3) 46 (2.6) Vein harvesting technique, n (%) 298 (67.9) 1,335 (76.3) No-touch technique 298 (67.9) 1,335 (76.3) Conventional technique 141 (32.1) 414 (23.7) Number of graft vessels, n (%) 0.052 1-2 211 (48.1) 735 (42.0) 3-4 212 (48.3) 955 (54.6) 5-6 16 (3.6) 59 (3.4) Operation time, n (%) ^{b, m} 0.286 <3 h | CABG | 324 (73.8) | 1,400 (80.1) | |
| CABG+other surgery 10 (2.3) 46 (2.6) Vein harvesting technique, n (%) <0.001 | CABG + valve | 105 (23.9) | 303 (17.3) | |
| Vein harvesting technique, n (%) | CABG + other surgery | 10 (2.3) | 46 (2.6) | |
| No-touch technique 298 (67.9) 1,335 (76.3) Conventional technique 141 (32.1) 414 (23.7) Number of graft vessels, n (%) | Vein harvesting technique, n (%) | | | < 0.001 |
| Conventional technique 141 (32.1) 414 (23.7) Number of graft vessels, n (%) 0.052 1-2 211 (48.1) 735 (42.0) 3-4 212 (48.3) 955 (54.6) 5-6 16 (3.6) 59 (3.4) Operation time, n (%) ^{b, m} 0.286 <3 h | No-touch technique | 298 (67.9) | 1,335 (76.3) | |
| Number of graft vessels, n (%) 0.052 1-2 211 (48.1) 735 (42.0) 3-4 212 (48.3) 955 (54.6) 5-6 16 (3.6) 59 (3.4) Operation time, n (%) ^{b, m} 0.286 <3 h | Conventional technique | 141 (32.1) | 414 (23.7) | |
| 1-2 211 (48.1) 735 (42.0) 3-4 212 (48.3) 955 (54.6) 5-6 16 (3.6) 59 (3.4) Operation time, n (%) ^{b, m} <3 h | Number of graft vessels, n (%) | | | 0.052 |
| 3-4 212 (48.3) 955 (54.6) 5-6 16 (3.6) 59 (3.4) 0.286 <3 h | 1–2 | 211 (48.1) | 735 (42.0) | |
| 5-6 16 (3.6) 59 (3.4) Operation time, n (%) ^{b, m} 0.286 <3 h | 3–4 | 212 (48.3) | 955 (54.6) | |
| Operation time, n (%) ^{b, m} 0.286 <3 h | 5–6 | 16 (3.6) | 59 (3.4) | |
| < <u>3 h</u> 78 (17.9) 322 (18.6) | Operation time, n (%) ^{b, m} | | | 0.286 |
| | <3 h | 78 (17.9) | 322 (18.6) | |

Table 2 (continued)

BMI=body mass index; CABG=coronary artery bypass grafting; DOAC=direct oral anticoagulant; LMWH=low-molecular-weight heparin; LVEF=left ventricular ejection fraction

Peripheral vascular disease = one or more of: claudication, carotid occlusion or 50% stenosis, previous or planned intervention on the abdominal aorta, limb arteries or carotids, or amputation for arterial disease

One character behind a variable indicates missing data in the men's group; two characters indicate missing data in both groups: ^aMissing data on two patients, ^bmissing data on three patients, ^cmissing data on 19 patients, ^dmissing data on one patient, ^emissing data on four patients, ^fmissing data on seven patients, ^gmissing data on five patients, ^hmissing data on 43 patients, ^lmissing data on ten patients, ^jmissing data on 20 patients, ^kmissing data on nine patients, ^lmissing data on 16 patients, ^mmissing data on 18 patients

¹Ex-smoker >1 month

consisted of 439 women (20%) and 1,749 men (80%), their ages ranging from 30 to 89 (median 70) years. Approximately 60% of the group were smokers or exsmokers and the majority had a BMI \geq 25. Altogether 374 (17.1%) patients received antibiotic treatment for any LWI; 154 (7.0%) also underwent surgical revision under local or general anaesthesia. Baseline characteristics are presented in Table 1.

The incidence of LWI at the harvest site was 23.7% in women and 15.4% in men (Table 1). Diabetes mellitus and anaemia were also more common among the women, as was impaired GFR. Moreover, there were more active smokers in the female group. The majority of the surgeries were elective but there was a tendency for the women to have more urgent operations as well as more combined interventions (CABG+valve surgery). Further differences between the sexes are described in Table 2.

Risk factors for any leg wound infection

In the multivariable logistic regression analysis, female sex [p<0.001; OR 1.62 (95% CI 1.22–2.16)], BMI≥30 [p<0.001; OR 2.04 (95% CI 1.42–2.93)], insulin-treated DM [p<0.001; OR 2.13 (95% CI 1.58–2.85)], peripheral vascular disease [p=0.028; OR 1.59 (95% CI 1.05–2.42)] and direct oral anticoagulants (DOACs) [p=0.015; OR 1.98 (95% CI 1.13–3.45)] were independently associated with any LWI (Table 3). Smoking was not associated with any statistically significant increased risk for LWI when added to the multivariable risk factor analysis. For additional details, see Table 3.

Risk factors for leg wound infection requiring surgical revision

In the multivariable analysis, female sex [p=0.007; OR 1.74 (95% CI 1.16–2.61)], insulin-treated DM [p<0.001; OR 2.95 (95% CI 1.95–4.46)], tablet-treated DM [p<0.001; OR 2.26 (95% CI 1.40–3.65)] and operation time >5 h [p=0.009; OR 1.75 (95% CI 1.15–2.67)] were independent risk factors for surgical revision. For further details, see Table 4.

Discussion

To date, only a few studies have investigated risk factors for LWI rate after CABG surgery [14]. We found female sex, medically treated DM, high BMI, DOAC treatment, and duration of surgery, as well as presence of peripheral vascular disease, to be independent predictive risk factors for LWI. The finding that female sex was an independent risk factor for LWI confirms earlier studies [14, 18, 21]. The underlying causes are unknown, but various assumptions and theories have been put forward as to why women have a higher incidence of LWI and other complications in vascular and cardiothoracic surgery. In other surgical procedures, men are more affected by SSI [19]. One theory, based on our own experiences, is that women in general have thinner skin on the legs than men, and therefore the skin is more fragile and difficult to heal. However, there are conflicting opinions about sex differences regarding the thickness of the epidermis. A recently published review article demonstrates weak evidence for this sex difference hypothesis [28]. Earlier research described the complexity of wound healing, pointing out that there is not one single explanation for all disparities [19, 29]. Wound healing is a complex physiological process. Disturbances in this process can lead to worse or delayed wound healing. Oestrogen deficiency has been shown to be detrimental for the wound healing process and postmenopausal women have an increased risk of complications as a result [30]. One hypothesis could be that the delayed wound healing process allows more time for bacteria to contaminate the wound. Oestrogen treatment could possibly reverse these effects of delayed wound healing [30]. Further, there is a theory that the different fat distribution in women and men affects both wound healing after surgery [31] and the outcome of the surgical procedure. Impaired peripheral circulation in women compared with men may be another explanation for women's increased risk of LWI [32].

In our study, smoking was not found to be a significant risk factor for LWI. Previous research on smoking and its impact on SSIs after different types of surgery has shown conflicting results [3, 22, 23]. A large study including data on major general surgical procedures indicated Table 3 Results of the univariable and multivariable logistic regression analysis of risk factors for any leg wound infection (LWI)

| | Unadjust | ed analysis | | Adjusted analysis [#] | | |
|------------------------------------|-------------|-------------|---------|--------------------------------|------------|---------|
| | OR | 95% CI | P-value | OR | 95% CI | P-value |
| Characteristics | | | | | | |
| Sex | | | | | | |
| Female | 1.70 | 1.31-2.19 | < 0.001 | 1.62 | 1.22-2.16 | < 0.001 |
| Male | Ref | | | | | |
| Age, yrs | | | | | | |
| 0–50 | 1.08 | 0.57-2.03 | 0.803 | | | |
| 51–60 | 0.83 | 0.58-1.17 | 0.298 | | | |
| 61–70 | 0.80 | 0.62-1.03 | 0.089 | | | |
| 71–80 | Ref | | | | | |
| 81–100 | 0.88 | 0.55-1.38 | 0.585 | | | |
| BMI, kg/m ² | | | | | | |
| <18.5 | 7.86 | 1.54-39.98 | 0.013 | 4.48 | 0.81-24.68 | 0.085 |
| 18.5-<25 | Ref | | | | | |
| 25-<30 | 1.40 | 1.00-1.95 | 0.048 | 1.35 | 0.95-1.91 | 0.089 |
| >30 | 2 47 | 1 76-3 47 | < 0.001 | 2 04 | 1 42-2 93 | < 0.001 |
| Diabetes mellitus | 2, | | (0.001 | 2.0 1 | 1112 2000 | 101001 |
| No | Ref | | | | | |
| Insulin-treated | 2 59 | 1 97-3 40 | <0.001 | 213 | 1 58-2 85 | < 0.001 |
| Tablet-treated | 1 47 | 1.05-2.05 | 0.023 | 1.26 | 0.88-1.80 | 0.203 |
| Diet-treated | 1.03 | 0.50-2.12 | 0.933 | 0.90 | 0.42-1.96 | 0.808 |
| Haemoglobin g/l | 1.05 | 0.50 2.12 | 0.955 | 0.90 | 0.12 1.90 | 0.000 |
| <120 | 1 / 3 | 1.05_1.95 | 0.023 | 1 10 | 0 77_1 55 | 0.592 |
| >121 | Rof | 1.05 1.55 | 0.025 | 1.10 | 0.77 1.55 | 0.372 |
| Penal function | nei | | | | | |
| Normal function | Pof | | | | | |
| Mild reduction | 1.05 | 002 124 | 0.699 | | | |
| Mederate reduction | 1.05 | 0.02-1.54 | 0.000 | | | |
| Source reduction | 0.44 | 0.07-1.07 | 0.241 | | | |
| Bonal failura | 1.10 | 0.10-1.09 | 0.270 | | | |
| Smaking | 1.12 | 0.24-3.20 | 0.079 | | | |
| Shoking | Def | | | | | |
| Never smoker | Rei 1.00 | 0.70 1.27 | 0.000 | 0.07 | 075 105 | 0.025 |
| EX-SITIOREI | 1.00 | 0.78-1.27 | 0.998 | 0.97 | 0.75-1.25 | 0.825 |
| Smoker | 1.30 | 0.90-1.88 | 0.148 | 1.12 | 0.76-1.66 | 0.554 |
| LVEF | | | | | | |
| >50% | Ref | 0.01 1.70 | 0.155 | | | |
| 41-50% | 1.25 | 0.91-1.70 | 0.155 | | | |
| 31-40% | 1.40 | 0.94-2.09 | 0.098 | | | |
| ≤30% | 1.68 | 1.03-2.75 | 0.036 | | | |
| Anticoagulants | | 0.00 4.54 | | | 0.04.4.50 | 0.004 |
| Heparin/LMWH | 1.15 | 0.88-1.51 | 0.280 | 1.15 | 0.86-1.52 | 0.331 |
| DOAC | 1.81 | 1.08-3.03 | 0.023 | 1.98 | 1.13-3.45 | 0.015 |
| No | Ref | | | | | |
| Peripheral vascular disease, n (%) | A | | | | | |
| No | Ref | | | | | |
| Yes | 1.61 | 1.08-2.38 | 0.018 | 1.59 | 1.05-2.42 | 0.028 |
| Operative factors | | | | | | |
| Degree of urgency | | | | | | |
| Emergency (within 24 h) | 1.17 | 0.68-2.00 | 0.555 | | | |
| Urgent | 1.13 | 0.90-1.44 | 0.278 | | | |
| Elective | Ref | | | | | |
| Type of intervention | | | | | | |
| CABG | Ref | | | | | |

Table 3 (continued)

| | Unadjusted analysis | | Adjusted analysis [#] | | | |
|---------------------------|---------------------|-----------|--------------------------------|------|-----------|---------|
| | OR | 95% CI | P-value | OR | 95% CI | P-value |
| CABG+valve | 1.18 | 0.89-1.56 | 0.234 | | | |
| CABG + other surgery | 1.69 | 0.91-3.14 | 0.093 | | | |
| Vein harvesting technique | | | | | | |
| No-touch technique | 1.16 | 0.89-1.51 | 0.247 | | | |
| Conventional technique | Ref | | | | | |
| Number of anastomoses | | | | | | |
| 1–2 | 0.80 | 0.63-1.01 | 0.060 | 0.79 | 0.61-1.01 | 0.064 |
| 3–4 | Ref | | | | | |
| 5–6 | 1.75 | 1.04-2.98 | 0.035 | 1.24 | 0.68-2.26 | 0.466 |
| Operation time | | | | | | |
| <3 h | 0.65 | 0.46-0.91 | 0.013 | 0.76 | 0.54-1.08 | 0.138 |
| 3–5 h | Ref | | | | | |
| >5 h | 1.64 | 1.23-2.19 | < 0.001 | 1.36 | 1.00-1.86 | 0.050 |

BMI=body mass index; CABG=coronary artery bypass grafting; CI=confidence interval; DOAC=direct oral anticoagulant; LMWH=low-molecular-weight heparin; LVEF=left ventricular ejection fraction; OR=odds ratio

Peripheral vascular disease = one or more of: claudication, carotid occlusion or 50% stenosis, previous or planned intervention on the abdominal aorta, limb arteries or carotids, or amputation for arterial disease

^aEx-smoker>1 month

[#]The model is adjusted for sex, diabetes mellitus, BMI, haemoglobin, smoking, anticoagulants, peripheral vascular disease, number of anastomoses and operation time

that smoking increases the risk of postoperative SSI and wound disruption [22]. Regardless of sex, age, duration of surgery or anaesthetic technique, current smoking was associated with a higher risk of postoperative wound complications compared with not smoking [22]. By contrast, and in line with the results of our study, smoking has not been shown to be an independent risk factor in previous studies on LWI after CABG surgery [14, 33]. Despite this, one study pointed out that leg wound healing disturbances in the form of wound edge necrosis and dehiscence were significantly higher in smokers than in non-smokers; but there were no differences between these two groups for LWIs [3]. Based on the findings of our study, in addition to earlier research, smoking can hardly be considered an important risk factor for occurrence of LWI after CABG.

Limitations

Our study was a single-centre study, which could potentially be a limitation regarding the external validity. An earlier study including national data from all cardiothoracic surgery centres in Sweden indicated that local traditions may be among the most important factors determining which procedures are employed in the operating theatre [34]. Such traditions would likely affect the external factors (operation time, type of sutures, vein harvesting technique, suturing experience, etc.) in the vein harvesting procedure. Furthermore, there are several issues with the definition of "smokers" and "ex-smokers", in terms of number of cigarettes per day and also of the smoke-free period for individuals to be termed "ex-smokers". We did not have data on the smokefree period. In other words, our ex-smokers could have stopped at any point between 1 month and 15 years previously.

The greatest strengths of this study are the high number of included patients and the quality of the registry.

Conclusion

In this study, female sex was an independent predictor for SSI at the harvest site after CABG surgery. The underlying mechanisms need to be further investigated. Previous or current smoking was not indicated as a risk factor for occurrence of LWI.

Table 4 Multivariable logistic regression analysis of risk factors for leg wound infection (LWI) requiring surgical revision

| | Unadiuste | | | | Adjusted analysis [#] | | |
|-----------------------------|-------------|-----------------|---------|-------|--------------------------------|-----------------|--|
| | OR | 95% CI | P-value | | 95% CI | <i>P</i> -value | |
| Characteristics | | 33 /0 Cl | / Value | on | | , vulue | |
| Sex | 1.90 | 1 33-2 72 | < 0.001 | 1 74 | 1 16-2 61 | 0.007 | |
| Female | 1.50 | 1.55 2.72 | (0.001 | 1.7 1 | 1.10 2.01 | 0.007 | |
| Male | | | | | | | |
| Ref | | | | | | | |
| Age, yrs | | | | | | | |
| 0–50 | 0.92 | 0.32-2.62 | 0.878 | | | | |
| 51–60 | 0.77 | 0.43-1.37 | 0.390 | | | | |
| 61–70 | 1.24 | 0.86-1.80 | 0.238 | | | | |
| 71–80 | Ref | | | | | | |
| 81–100 | 1.08 | 0.55-2.11 | 0.820 | | | | |
| Diabetes mellitus | | | | | | | |
| No | Ref | 2.28-4.87 | < 0.001 | 2.95 | 1.95-4.46 | < 0.001 | |
| Insulin-treated | 3.33 | | | | | | |
| Tablet-treated | 2.30 | 1.47-3.62 | <0.001 | 2.26 | 1.40-3.65 | < 0.001 | |
| Diet-treated | 0.64 | 0.15-2.69 | 0.547 | 0.69 | 0.16-2.94 | 0.625 | |
| BMI, kg/m ² | | | | | | | |
| BMI <18.5 | NE | | | | | | |
| BMI 18.5-<25 | Ref | | | | | | |
| BMI 25-<30 | 1.83 | 1.09-3.07 | 0.020 | 1.83 | 1.06-3.17 | 0.028 | |
| $BMI \ge 30$ | 2.21 | 1.29-3.76 | 0.003 | 1.68 | 0.95-2.98 | 0.074 | |
| Haemoglobin, g/L | | | | | | | |
| ≤120 | 1.83 | 1.20-2.77 | 0.004 | 1.29 | 0.81-2.06 | 0.282 | |
| ≥121 | Ref | | | | | | |
| Renal function | | | | | | | |
| Normal function | Ref | | | | | | |
| Mild reduction | 1.11 | 0.77-1.60 | 0.576 | | | | |
| Moderate reduction | 1 31 | 0.82-2.09 | 0.254 | | | | |
| Severe reduction | 1.25 | 0 29–5 46 | 0.758 | | | | |
| Renal failure | 1.23 | 0.18-11.5 | 0.726 | | | | |
| Smoking | 1.11 | 0.10 11.5 | 0.720 | | | | |
| Ex-smoker ^a | 0.90 | 0.62-1.30 | 0 584 | 0.88 | 0.60-1.29 | 0.526 | |
| Smoker | 1.67 | 1.02_2.74 | 0.040 | 1 33 | 0.78_2.25 | 0.320 | |
| Never smoker | Ref | 1.02 2.7 1 | 0.010 | 1.55 | 0.70 2.25 | 0.291 | |
| | nei | | | | | | |
| > 5004 | Pof | | | | | | |
| 250% 41 50% | 1 20 | | 0.264 | | | | |
| 21 4004 | 1.29 | 1.01. 2.02 | 0.204 | | | | |
| 51-40% <20% | 1.75 | 0.07 2.45 | 0.040 | | | | |
| | 1./4 | 0.67-5.45 | 0.115 | | | | |
| | 0.02 | 0(1 14 | 0.720 | | | | |
| | 0.93 | 0.01-1.4 | 0.739 | | | | |
| DUAC | 1.69 D-f | 0.82-3.48 | 0.150 | | | | |
| | Ret | | | | | | |
| Peripheral Vascular disease | 1 77 | 104 202 | 0.025 | 1.66 | 0.04, 0.00 | 0.000 | |
| Yes | 1.// | 1.04-3.03 | 0.035 | 1.66 | 0.94-2.93 | 0.080 | |
| | Ket | | | | | | |
| Operative factors | | | | | | | |
| Degree of urgency | | | | | | | |
| Emergency (within 24 h) | 1.61 | 0.80-3.21 | 0.175 | | | | |
| Urgent | 1.10 | 0.78–1.56 | 0.566 | | | | |
| Elective | Ref | | | | | | |
| Type of intervention | | | | | | | |
| CABG | Ref | | | | | | |

Table 4 (continued)

| | Unadjusted analysis | | | Adjusted analysis [#] | | |
|---------------------------|---------------------|-----------|---------|--------------------------------|-----------|---------|
| | OR | 95% CI | P-value | OR | 95% CI | P-value |
| CABG + valve | 0.90 | 0.58-1.39 | 0.643 | | | |
| CABG + other surgery | 1.89 | 0.83-4.26 | 0.124 | | | |
| Vein harvesting technique | | | | | | |
| No-touch technique | 1.16 | 0.79-1.72 | 0.436 | | | |
| Conventional technique | Ref | | | | | |
| Number of anastomoses | | | | | | |
| 1–2 | 0.88 | 0.62-1.24 | 0.470 | 0.96 | 0.66-1.38 | 0.832 |
| 3–4 | Ref | | | | | |
| 5–6 | 2.77 | 1.46-5.25 | 0.002 | 1.63 | 0.77-3.48 | 0.199 |
| Operation time | | | | | | |
| Operation time <3 h | 0.65 | 0.38-1.10 | 0.114 | 0.69 | 0.39-1.20 | 0.197 |
| Operation time 3–5 h | | | | | | |
| Operation time >5 h | 2.25 | 1.53-3.31 | < 0.001 | 1.75 | 1.15-2.67 | 0.009 |

BMI=body mass index; CABG=coronary artery bypass grafting; CI=confidence interval; DOAC=direct oral anticoagulant; LMWH=low-molecular-weight heparin; LVEF=left ventricular ejection fraction; OR=odds ratio; NE=not estimatable

Peripheral vascular disease = one or more of: claudication, carotid occlusion or 50% stenosis, previous or planned intervention on the abdominal aorta, limb arteries or carotids, or amputation for arterial disease

^aEx-smoker>1 month

[#]The model is adjusted for sex, diabetes mellitus, BMI, haemoglobin, smoking, peripheral vascular disease, number of anastomoses and operation time

Acknowledgements

The authors would like to thank statistician Snehal Patil, for her invaluable help and statistical support to this study.

Author contributions

H.U. Conceptualization, Methodology, Formal analysis, Writing - Original Draft, Writing - Review & Editing, Visualization. M.H-N., K.F-B. and Ö.F. Conceptualization, Methodology, Formal analysis, Writing - Original Draft, Writing - Review & Editing, Supervision. All authors read and approved the final manuscript.

Funding

This study was supported by Örebro University Hospital research committee. Open access funding provided by Örebro University.

Data availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study was approved by the Swedish Ethical Review Authority (ID 2020–03103). Because of the retrospective nature of the study no informed consent was obtained.

Competing interests

The authors declare no competing interests.

Received: 21 December 2023 / Accepted: 25 May 2024 Published online: 31 May 2024

References

- Jessen ME. Efforts to improve bypass graft patency have not been in vein. J Thorac Cardiovasc Surg. 2015;150(4):889–90.
- Deb S, Singh SK, de Souza D, Chu MWA, Whitlock R, Meyer SR, et al. SUPERIOR SVG: no touch saphenous harvesting to improve patency following coronary bypass grafting (a multi-centre randomized control trial, NCT01047449). J Cardiothorac Surg. 2019;14(1):85.

- Sharif-Kashani B, Shahabi P, Mandegar MH, Saliminejad L, Bikdeli B, Behzadnia N, et al. Smoking and wound complications after coronary artery bypass grafting. J Surg Res. 2016;200(2):743–8.
- Meszaros K, Fuehrer U, Grogg S, Sodeck G, Czerny M, Marschall J, et al. Risk factors for Sternal wound infection after Open Heart Operations Vary according to type of operation. Ann Thorac Surg. 2016;101(4):1418–25.
- Gudbjartsson T, Jeppsson A, Sjogren J, Steingrimsson S, Geirsson A, Friberg O, et al. Sternal wound infections following open heart surgery - a review. Scand Cardiovasc J. 2016;50(5–6):341–8.
- Larsson H, Nyman MH, Brynhildsen KF. Patients' experiences regarding severe leg wound infection associated with coronary artery bypass grafting: a qualitative study. J Vasc Nurs. 2022.
- Allegranzi B, Bischoff P, de Jonge S, Kubilay NZ, Zayed B, Gomes SM, et al. New WHO recommendations on preoperative measures for surgical site infection prevention: an evidence-based global perspective. Lancet Infect Dis. 2016;16(12):e276–87.
- Riksföreningen för operationssjukvård & svensk sjuksköterskeförening. Kompetensbeskrivning för legitimerad sjuksköterska med specialistsjuksköterskeexamen inriktning mot operationssjukvård Stockholm: Riksföreningen för operationssjukvård & svensk sjuksköterskeförening; 2011 [cited 2019 May 22]. http://www.rfop.se/media/1254/kompbeskrivning.pdf.
- Kelvered M, Ohlen J, Gustafsson BA. Operating theatre nurses' experience of patient-related, intraoperative nursing care. Scand J Caring Sci. 2012;26(3):449–57.
- Caliskan E, de Souza DR, Boning A, Liakopoulos OJ, Choi YH, Pepper J, et al. Saphenous vein grafts in contemporary coronary artery bypass graft surgery. Nat Rev Cardiol. 2020;17(3):155–69.
- Filip T, Schrother F, Haase R, Rudolph N, Claus T, Albes JM. Patient satisfaction and clinical complications after Endoscopic or Surgical Saphenous Vein Harvesting. Thorac Cardiovasc Surg. 2020;68(8):700–5.
- Tian M, Wang X, Sun H, Feng W, Song Y, Lu F, et al. No-Touch Versus Conventional Vein Harvesting techniques at 12 months after coronary artery bypass grafting surgery: Multicenter Randomized, Controlled Trial. Circulation. 2021;144(14):1120–9.
- Sharma M, Fakih MG, Berriel-Cass D, Meisner S, Saravolatz L, Khatib R. Harvest surgical site infection following coronary artery bypass grafting: risk factors, microbiology, and outcomes. Am J Infect Control. 2009;37(8):653–7.
- Hassoun-Kheir N, Hasid I, Bozhko M, Shaban Z, Glam R, Hussein K, et al. Risk factors for limb surgical site infection following coronary artery bypass graft using open great saphenous vein harvesting: a retrospective cohort study. Interact Cardiovasc Thorac Surg. 2018;27(4):530–5.

- Seim BE, Tonnessen T, Woldbaek PR. Triclosan-coated sutures do not reduce leg wound infections after coronary artery bypass grafting. Interact Cardiovasc Thorac Surg. 2012;15(3):411–5.
- Thimour-Bergstrom L, Roman-Emanuel C, Schersten H, Friberg O, Gudbjartsson T, Jeppsson A. Triclosan-coated sutures reduce surgical site infection after open vein harvesting in coronary artery bypass grafting patients: a randomized controlled trial. Eur J Cardiothorac Surg. 2013;44(5):931–8.
- Stenvik M, Tjomsland O, Lien S, Gunnes S, Kirkeby-Garstad I, Astudillo R. Effect of subcutaneous suture line and surgical technique on wound infection after saphenectomy in coronary artery bypass grafting: a prospective randomised study. Scand Cardiovasc J. 2006;40(4):234–7.
- Olsen MA, Sundt TM, Lawton JS, Damiano RJ Jr., Hopkins-Broyles D, Lock-Buckley P, et al. Risk factors for leg harvest surgical site infections after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg. 2003;126(4):992–9.
- Aghdassi SJS, Schroder C, Gastmeier P. Gender-related risk factors for surgical site infections. Results from 10 years of surveillance in Germany. Antimicrob Resist Infect Control. 2019;8:95.
- Alghamdi BA, Alharthi RA, AlShaikh BA, Alosaimi MA, Alghamdi AY, Yusnoraini N, et al. Risk factors for post-cardiac surgery infections. Cureus. 2022;14(11):e31198.
- Siddiqi S. Saphenous vein harvest wound complications: risk factors, identification, prevention, and management. Chronic Wound Care Manage Res. 2016;3:147–56.
- 22. Fan Chiang YH, Lee YW, Lam F, Liao CC, Chang CC, Lin CS. Smoking increases the risk of postoperative wound complications: a propensity score-matched cohort study. Int Wound J. 2023;20(2):391–402.
- Schmid M, Sood A, Campbell L, Kapoor V, Dalela D, Klett DE, et al. Impact of smoking on perioperative outcomes after major surgery. Am J Surg. 2015;210(2):221–9. e6.
- 24. Souza D. A new no-touch preparation technique. Technical notes. Scand J Thorac Cardiovasc Surg. 1996;30(1):41–4.
- Carath ett verksamhetsinitierat kvalitetsregister och processtöd. Ger toraxkirurgin bra möjlighet att följa vårdprocessen Läkartidningen: Läkartidningen Förlag AB; 2011 [cited 2023 14 February]. https://lakartidningen.se/klinik-och-vetenskap-1/2011/06/ carath-ett-verksamhetsinitierat-kvalitetsregister-och-processtod/.

- National Healthcare Safety Network. Prevention. CfDCa. Surgical site infection (SSI) event. 2023. https://www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent. pdf. [cited 2023 27 October].
- Wilson APTT, Sturridge MF, Grüneberg RN. A scoring method (ASEPSIS) for postoperative wound infections for use in clinical trials of antibiotic prophylaxis. Lancet. 1986;1:311–3.
- Lintzeri DA, Karimian N, Blume-Peytavi U, Kottner J. Epidermal thickness in healthy humans: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2022;36(8):1191–200.
- Nurkkala J, Kauko A, Palmu J, Aittokallio J, Niiranen T. Sex differences in coronary artery bypass grafting-related morbidity and mortality. Front Cardiovasc Med. 2022;9:1021363.
- Horng HC, Chang WH, Yeh CC, Huang BS, Chang CP, Chen YJ et al. Estrogen effects on Wound Healing. Int J Mol Sci. 2017;18(11).
- Arnaoutakis DJ, Scully RE, Sharma G, Shah SK, Ozaki CK, Belkin M, et al. Impact of body mass index and gender on wound complications after lower extremity arterial surgery. J Vasc Surg. 2017;65(6):1713–e81.
- Friedman ND, Bull PLRAL, Richards MJ, Kelly H. Validation of coronary artery bypass graft surgical site infection surveillance data from a statewide surveillance system in Australia. Infect Control Hosp Epidemiol. 2007;28:812–7.
- Swenne CL, Borowiec J, Carlsson M, Lindholm C. Prediction of and risk factors for surgical wound infection in the saphenous vein harvesting leg in patients undergoing coronary artery bypass. Thorac Cardiovasc Surg. 2006;54(5):300–6.
- Larsson H, Halleberg-Nyman M, Friberg O, Falk-Brynhildsen K. Perioperative routines and surgical techniques for saphenous vein harvesting in CABG surgery: a national cross-sectional study in Sweden. J Cardiothorac Surg. 2020;15(1):5.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.